HeJing

Hejing Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of next-generation cell therapies for oncology. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies, with a particular emphasis on overcoming the limitations of current autologous treatments through universal, off-the-shelf platforms. Their pipeline includes candidates targeting hematological malignancies such as B-cell lymphoma and multiple myeloma, as well as solid tumors like liver and pancreatic cancer. By leveraging advanced gene editing and cell engineering, Hejing aims to provide more accessible and effective immunotherapy options for patients globally.